Southwest Hematology Oncology Conference: Precision Guided Therapy

Phoenix, AZ US
August 10, 2024

The Southwest Hematology Oncology Conference: Precision Guided Therapy is a 1-day educational and scientific meeting that will focus on the updates in the biomarker-guided management of patients with common malignancies. This conference will feature experts discussing the latest diagnostic, therapeutic, and supportive care strategies in cancer management. In addition, expert faculty will place recent practice-changing updates into a clinical context and discuss how the results may change the current standards of care. The goals of this conference are to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to incorporate biomarker-guided therapy in the management of patients with cancer.

Target Audience

  • Hematologists/Medical oncologists
  • Primary care providers
  • Resident/fellows
  • NPs/PAs
  • Pharmacists
  • Oncology Nurses

ORGANIZING COMMITTEE

Course Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Chairs:

 Sumit Madan, MD - Banner MD Anderson

 Tibor Kovacsovics, MD - City of Hope Phoenix

Learning Objectives

  • Discuss the current and evolving paradigms in precision oncology, across various specialty areas and malignancies.
  • Describe the different testing methodologies available to guide targeted therapies and their appropriate timing.
  • Explain the concept of “tumor agnostic” therapeutics and identify opportunities to optimize treatment planning and side effect management in different malignancies.
  • Discuss how to foster a multi-disciplinary approach to care, collaboration among providers, and how to increase knowledge of and participation in clinical trials.

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
05/20/2024
Course expires: 
08/10/2025
Event starts: 
08/10/2024 - 8:00am PDT
Event ends: 
08/10/2024 - 4:52pm PDT
Cost:
$350.00

August 10th, 2024

All times are listed in the local time zone.

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:25 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:25 AM – 09:30 AM  Session 1 - Plasma Cell Disorders

Session Chair: Sumit Madan, MD

08:25 AM – 08:40 AM  Promises of Personalized Medicine: Exploring the Genetic Landscape in Myeloma - Jonathan Keats, PhD

08:40 AM – 08:55 AM  Upfront Treatment of High-Risk Myeloma - Jeremy T. Larsen, MD

08:55 AM – 09:10 AM  CAR-T vs Bispecifics: How to Sequence Immunotherapies - Saurabh Chhabra, MBBS

09:10 AM – 09:20 AM  Thinking Beyond Daratumumab and Cybord in AL Amyloidosis - Tibor Kovacsovics, MD

09:20 AM – 09:30 AM  Discussion


09:30 AM – 10:00 AM  Break & Exhibits


10:00 AM – 11:00 AM  Session 2 - Myeloid Malignancies

Session Chair: Tibor Kovacsovics, MD & Sharad Khurana, MD

10:00 AM – 10:15 AM  Management of AML - Focus on Disease and Patient Factors - Roland Walter, MD, PhD, MS

10:15 AM – 10:30 AM  Updates in the Management of CML - Neil Pravin Shah, MD, PhD

10:30 AM – 10:45 AM  Initiating and Sequencing  Treatments of  Primary Myelofibrosis in 2024 - Guru Subramanian Guru Murthy, MD, MS

10:45 AM – 11:00 AM  Discussion


11:00 AM – 12:00 PM  Session 3 - Lymphoid Malignancies

Session Chair: Matthew Ulrickson, MD

11:00 AM – 11:15 AM Management of newly diagnosed lymphomas in the era of novel therapies - Allison C. Rosenthal, D.O.

11:15 AM – 11:30 AM Novel therapies in relapsed NHLs - Javier L. Munoz, MD, MBA

11:30 AM – 11:45 PM Case-based Discussion - Zoey I. Harris, MD

11:45 AM – 12:00 PM Discussion


12:00 PM – 01:00 PM  Lunch & Exhibits

12:15 PM  01:00 PM  Product Theater Sponsored by Merck in Borein AB

Topic: A Treatment Option for Adult Patients With Locally Advanced or Metastatic Urothelial Cancer

Speaker: Michael Lattanzi, MD

* This is a non-CME activity *


01:00 PM – 02:00 PM  Session 4 - Thoracic Oncology

Session Chair: Jiaxin Niu, MD

01:00 PM – 01:15 PM  Advances in Precision-Guided Therapy in NSCLC - Vinicius Ernani, M.D

01:15 PM – 01:30 PM  Immunotherapy in Lung Cancer: Current and Evolving Strategies - Vamsee Torri, MD

01:30 PM – 01:45 PM  Case-Based Discussion - Aida Amado, ACNP

01:45 PM – 02:00 PM  Discussion 


02:00 PM – 03:00 PM  Session 5 - General Oncology

Session Chair: Chad Cherington, MD

02:00 PM – 02:15 PM  GI Oncology: Updates in Precision-Guided Therapy - Tanios S. Bekaii-Saab, MD

02:15 PM – 02:30 PM  Precision-Guided Approach in Managing GU Malignancies - Jason Brown, MD, PhD

02:30 PM – 02:45 PM  Precision-Guided Therapy in Sarcoma - Mahesh Seetharam, MD, FACP, MBBS

02:45 PM – 03:00 PM  Case-based Discussion- ct DNA in GU Oncology- Yousef Zakharia, MD


03:00 PM – 03:15 PM  Break & Exhibits


03:15 PM – 04:15 PM  Session 6 - Breast Cancer

Session Chair: Qing Zhao, MD

03:15 PM – 03:30 PM  Molecular-Guided Therapy in Breast Cancer - Qing Zhao, MD

03:30 PM – 03:45 PM  Case-based Discussion - Karen S. Anderson, MD, PhD

03:45 PM – 04:15 PM  Discussion - Hung Khong MD


04:15 PM  Adjourn

Hyatt Regency Phoenix
122 N 2nd St,
Phoenix, AZ 85004
United States
+1 (602) 252-1234

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Tibor Kovacsovics, MD

has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Syndax;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Glycomimetics;.
has a financial relationship (Other) with Servier;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Other) with Rigel;.

Sumit Madan

has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Karyopharm;.
Session Chair(s)

Sharad Khurana, MD, MSc

has no relevant financial relationships to disclose at this time.

Jiaxin Niu

has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Britol Myers Squibb;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Pfizer;.

Matthew Ulrickson, MD

has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Travel) with Miltenyi;.

Qing Zhao, MD, MS

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Tanios Bekaii-Saab, MD

has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Merus;.
has a financial relationship (Professional Services) with Agios;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Boston Biomedical;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Caladrius Biosciences;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Abgenomics;.
has a financial relationship (Professional Services) with Servier;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with Stemline;.
has a financial relationship (Professional Services) with Atreca;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Celularity;.
has a financial relationship (Professional Services) with Seattle Genetics;.
has a financial relationship (Professional Services) with Merus;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Incyte;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Arcus;.
has a financial relationship (Professional Services) with Boehringer Ingelheim,;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with TreosBio;.
has a financial relationship (Professional Services) with Clovis;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Arcus;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Merck KGaA;.
has a financial relationship (Professional Services) with Arys;.
has a financial relationship (Professional Services) with Blue print medicines ;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Natera;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Incyte;.

Jason Brown

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with EMD Serono;.

Saurabh Chhabra

has a financial relationship (Grant Or Contract) with CARSgen;.
has a financial relationship (Grant Or Contract) with Johnson & Johnson;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Grant Or Contract) with C4 Therapeutics;.
has a financial relationship (Other) with Ascentage Pharma;.
has a financial relationship (Grant Or Contract) with AbbVie;.
has a financial relationship (Other) with Sanofi;.

Vinicius Ernani, M.D

has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with AstraZeneca;.

Guru Subramanian Guru Murthy, MD, MS

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Other) with Kite;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Rigel;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Other) with Amgen;.

Jonathan Keats, PhD

has no relevant financial relationships to disclose at this time.

jeremy larsen

has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Independent contractor) with Abbvie;.

Javier Munoz, MD MS MBA

has a financial relationship (Professional Services) with Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte;.
has a financial relationship (Other) with Targeted Oncology, OncView, Curio, and Physicians' Education Resource;.
has a financial relationship (Financial Support) with Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene;.
has a financial relationship (Professional Services) with MEI, TG Therapeutics, AstraZeneca, Eli Lilly;.

Allison Rosenthal, DO

has no relevant financial relationships to disclose at this time.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Neil Shah, MD PhD

has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.

Vamsee Torri

has no relevant financial relationships to disclose at this time.

Roland Walter, MD PhD MS

has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with ImmunoGen;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Stock Options) with Amphivena;.
Case Presenter(s)

Aida Amado, MSN, ACNP-BC, AOCNP

has no relevant financial relationships to disclose at this time.

Karen Anderson, Professor, Arizona State University, Mayo Clinic Arizona

has a financial relationship (Independent contractor) with Effector;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Stock Options) with FlexBioTech;.

Zoey Harris

has no relevant financial relationships to disclose at this time.

Hung Khong, MD

has a financial relationship (Stock) with Agenus;.
has a financial relationship (Stock) with MiNK Therapeutics;.
has a financial relationship (Stock) with TG Therapeutics;.

Yousef Zakharia, MD

has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead ;.
has a financial relationship (Professional Services) with Seagen ;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Eisai ;.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Vendor List - Phoenix Aug 2024  
   
NameSponsorship typeRequester  Name
EMD SorenoGeneral ExhibitNicholette Breier
Merck - Lunch PTLunch PTDonna Roberts
AstraZenecaGeneral ExhibitTracy Wallace
Daiichi SankyoPremium ExhibitJarrett Mitchell
AmgenGeneral ExhibitSarah Ahadome
SpringWorks TherapeuticsGeneral ExhibitElise Rosenthal
TakedaPremium ExhibitKeith Thompson
PfizerGeneral ExhibitEllie Shadewald
Johnson & Johnson Innovative MedicineGeneral ExhibitLisa  Talley
Lilly OncologyGeneral ExhibitKevin J. McGowan
IncyteGeneral ExhibitDaniel Stefl
GenmabGeneral ExhibitSonia Sample
Puma BiotechGeneral ExhibitJennifer Pylman
RegeneronGeneral ExhibitShelby Mcqueen
MerckGeneral ExhibitJosh Boersma
   
   
   

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.